In 2014 was created Roivant Sciences, which is appeared as Corporate Investor. The company was established in Europe in Switzerland. The leading representative office of defined Corporate Investor is situated in the Basel.
The fund has no exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Data Integration, Clinical Trials. Among the most popular portfolio startups of the fund, we may highlight Datavant, Arbutus Biopharma. Moreover, a startup needs to be at the age of 11-15 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - Canada.
The current fund was established by Vivek Ramaswamy.
The usual cause for the fund is to invest in rounds with 3 partakers. The meaningful sponsors for the fund in investment in the same round are Travis May, Tom Chavez, SoftBank Investment Advisers.
The important activity for fund was in 2017. The higher amount of exits for fund were in 2010. The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 50 - 100 millions dollars are the general things for fund.
Related Funds
| Fund Name | Location |
| Animal Capital | California, Los Angeles, United States |
| Centralway Ventures | Switzerland, Zürich, Zurich |
| China Life Private Equity Investment | Beijing, Beijing, China |
| CNF Investments, LLC | Bethesda, Maryland, United States |
| CNNSI.com | - |
| Digital-Healthcare | England, Leeds, United Kingdom |
| Elevation Capital | Gurgaon, Haryana, India |
| Epic Foundation | New York, New York, United States |
| Frankford Re | - |
| Haier Homecare | - |
| Helios Enterprises | - |
| Impact Capital Holdings | - |
| Kingdom Engine | China, Guangdong, Shenzhen |
| Rosemark Capital Group | New Jersey, Princeton, United States |
| Sapphire Capital Partners | England, London, United Kingdom |
| Silverhorn Investment Advisors | - |
| Velcourt | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Lokavant | $21M | 07 Dec 2022 | New York, New York, United States | ||
Medallion | $30M | 03 Nov 2021 | San Francisco, California, United States | ||
gen-t | $2M | 01 Nov 2021 | Sao Paulo, São Paulo, Brazil | ||
Datavant | $40M | 08 Oct 2020 | San Francisco, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Lokavant | $21M | 07 Dec 2022 | New York, New York, United States | ||
Medallion | $30M | 03 Nov 2021 | San Francisco, California, United States | ||
gen-t | $2M | 01 Nov 2021 | Sao Paulo, São Paulo, Brazil | ||
Datavant | $40M | 08 Oct 2020 | San Francisco, California, United States |
